TIXiMED's TIX100 clears Phase 1a safety bar, moves to 28-day dosing study
The oral TXNIP inhibitor was well tolerated across four single-dose cohorts and lowered post-meal glucose swings in healthy volunteers, clearing the way for a placebo-controlled multiple-dose study.
Executive Summary
- TIXiMED's single ascending dose study of TIX100 met its safety-focused design goals across all dose levels tested in healthy volunteers, with no hypoglycemia even under extended fasting.
- Beyond tolerability, the study produced the first metabolic readout for TIX100 in humans: a reduction in the glucose spike that follows a meal, an effect consistent with the drug's proposed mechanism but not yet tested in anyone with diabetes.
- The company is using the result to justify moving straight into a placebo-controlled, multiple-dose study that will generate the longer safety data needed before a planned trial in people recently diagnosed with type 1 diabetes.
- A single dose in healthy, normoglycemic volunteers on safety endpoints cannot establish whether TIX100 protects insulin-producing beta cells or slows disease progression, the therapeutic hypothesis the whole program rests on.
The readout
TIXiMED disclosed on July 7, 2026 that its Phase 1a single ascending dose study of TIX100 had completed, enrolling 35 healthy volunteers under NCT06800729. The trial's five registered primary endpoints were all safety measures: clinically significant findings on ECG, lab values above the upper limit of normal, physical exam findings, treatment-related adverse events graded by CTCAE v5.0, and vital signs. The company said TIX100 was safe and well tolerated across all four dose cohorts and produced no hypoglycemia even during extended fasting. NCT06800729+1A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy SubjectsNCT06800729TIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100Jul 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The glucose signal
Alongside the safety data, TIXiMED reported that TIX100 lowered postprandial glucose excursion, the rise in blood sugar after a meal, in the healthy, normoglycemic study population. The company called this the first metabolic signal of TIX100 in humans. Chief Scientific Officer Anath Shalev said the single-dose study gave the company "a first metabolic signal in humans, and the MAD study will generate the longer-term safety data we need before advancing into a Phase 2a study including people with recent-onset type 1 diabetes". That endpoint sits outside the trial's five registered primary safety measures, and the disclosure itself was flagged for emphasizing it prominently. TIXiMEDTIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100Jul 7, 2026
What TIX100 targets
TIX100 is designed to inhibit thioredoxin-interacting protein (TXNIP), a protein the company says is elevated in diabetes and drives loss of insulin-producing pancreatic beta cells. TIXiMED says two decades of research identified TXNIP as a driver of beta-cell loss in mouse models and in people with type 1 diabetes, and that inhibiting it protects beta cells and supports islet health. No other industry-sponsored trial in the reviewed competitive set targets TXNIP in this population, leaving TIX100 without a direct same-mechanism comparator to benchmark against. TIXiMEDTIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100Jul 7, 2026
The next study
TIXiMED has already moved to the next step: a Phase 1b multiple ascending dose study (NCT07675590) that will enroll 18 healthy subjects across three dose cohorts at a single US site, randomizing each cohort to TIX100 or placebo twice daily for 28 days followed by a seven-day follow-up. That double-blind, placebo-controlled design is intended to generate the longer-term safety data the company says it needs before advancing into a Phase 2a trial that would, for the first time, include people with recent-onset type 1 diabetes. CEO Stephen Daly said people at all stages of type 1 diabetes "still have no oral options or therapy designed to address the underlying damage to islet biology". TIXiMEDTIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100Jul 7, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.